Skip to main content
SpringerLink
Log in

Abdominal Infection

  • Chapter
  • First Online:
The Infectious Diseases Consult Handbook

  • 282 Accesses

Abstract

The abdomen features a number of organs important in digestion, metabolism, and detoxification, including the intestines, liver, biliary system, and spleen. The intestines and hepatobiliary system have a thriving community of bacterial and fungal flora known as the gut microbiome. While these commensal organisms can assist in processes such as digestion and modification of certain nutrients, disruptions in the microbiome can cause overproliferation of pathogenic species. In addition, insults to the epithelial barrier, such as chemotherapy or autoimmune disease, can result in systemic translocation of abdominal organisms.

In this chapter, we will discuss the duration of treatment for abdominal infections, disease involving specific organs (such as the appendix, liver, and spleen), Clostridioides difficile diagnosis and management, and some special examples of abdominal pathology such as fungal infection in patients undergoing peritoneal dialysis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, Cook CH, O’Neill PJ, Mazuski JE, Askari R, Wilson MA, Napolitano LM, Namias N, Miller PR, Dellinger EP, Watson CM, Coimbra R, Dent DL, Lowry SF, Cocanour CS, West MA, Banton KL, Cheadle WG, Lipsett PA, Guidry CA, Popovsky K. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;372:1996–2005. https://doi.org/10.1056/NEJMoa1411162.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Montravers P, Tubach F, Lescot T, Veber B, Esposito-Farèse M, Seguin P, Paugam C, Lepape A, Meistelman C, Cousson J, Tesniere A, Plantefeve G, Blasco G, Asehnoune K, Jaber S, Lasocki S, Dupont H, DURAPOP Trial Group. Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOP randomised clinical trial. Intensive Care Med. 2018;44:300–10. https://doi.org/10.1007/s00134-018-5088-x.

    Article  CAS  PubMed  Google Scholar 

  3. Salminen P, Tuominen R, Paajanen H, Rautio T, Nordström P, Aarnio M, Rantanen T, Hurme S, Mecklin J-P, Sand J, Virtanen J, Jartti A, Grönroos JM. Five-year follow-up of antibiotic therapy for uncomplicated acute appendicitis in the APPAC randomized clinical trial. JAMA. 2018;320:1259–65. https://doi.org/10.1001/jama.2018.13201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Salminen P, Paajanen H, Rautio T, Nordström P, Aarnio M, Rantanen T, Tuominen R, Hurme S, Virtanen J, Mecklin J-P, Sand J, Jartti A, Rinta-Kiikka I, Grönroos JM. Antibiotic therapy vs appendectomy for treatment of uncomplicated acute appendicitis: the APPAC randomized clinical trial. JAMA. 2015;313:2340–8. https://doi.org/10.1001/jama.2015.6154.

    Article  CAS  PubMed  Google Scholar 

  5. Podda M, Gerardi C, Cillara N, Fearnhead N, Gomes CA, Birindelli A, Mulliri A, Davies RJ, Di Saverio S. Antibiotic treatment and appendectomy for uncomplicated acute appendicitis in adults and children: a systematic review and meta-analysis. Ann Surg. 2019;270:1028–40. https://doi.org/10.1097/SLA.0000000000003225.

    Article  PubMed  Google Scholar 

  6. Sippola S, Haijanen J, Grönroos J, Rautio T, Nordström P, Rantanen T, Pinta T, Ilves I, Mattila A, Rintala J, Löyttyniemi E, Hurme S, Tammilehto V, Marttila H, Meriläinen S, Laukkarinen J, Sävelä E-L, Savolainen H, Sippola T, Aarnio M, Paajanen H, Salminen P. Effect of oral moxifloxacin vs intravenous ertapenem plus Oral levofloxacin for treatment of uncomplicated acute appendicitis: the APPAC II randomized clinical trial. JAMA. 2021;325:353–62. https://doi.org/10.1001/jama.2020.23525.

    Article  CAS  PubMed  Google Scholar 

  7. Johannsen EC, Sifri CD, Madoff LC. Pyogenic liver abscesses. Infect Dis Clin N Am. 2000;14:547–63, vii. https://doi.org/10.1016/s0891-5520(05)70120-3.

    Article  CAS  Google Scholar 

  8. Wichmann D, Königsrainer A, Schweizer U, Archid R, Nadalin S, Manncke S. Pyogenic liver abscesses caused by acute appendicitis: frequency and diagnostic and therapeutic recommendations. Surg Infect. 2021;22:253–7. https://doi.org/10.1089/sur.2019.366.

    Article  Google Scholar 

  9. Serraino C, Elia C, Bracco C, Rinaldi G, Pomero F, Silvestri A, Melchio R, Fenoglio LM. Characteristics and management of pyogenic liver abscess: a European experience. Medicine (Baltimore). 2018;97:e0628. https://doi.org/10.1097/MD.0000000000010628.

    Article  PubMed  Google Scholar 

  10. Yin D, Ji C, Zhang S, Wang J, Lu Z, Song X, Jiang H, Lau WY, Liu L. Clinical characteristics and management of 1572 patients with pyogenic liver abscess: a 12-year retrospective study. Liver Int. 2021;41:810–8. https://doi.org/10.1111/liv.14760.

    Article  CAS  PubMed  Google Scholar 

  11. Chung YFA, Tan YM, Lui HF, Tay KH, Lo RHG, Kurup A, Tan BH. Management of pyogenic liver abscesses—percutaneous or open drainage. Singap Med J. 2007;48:1158–65. quiz 1165.

    CAS  Google Scholar 

  12. Lewis JH, Patel HR, Zimmerman HJ. The spectrum of hepatic candidiasis. Hepatology. 1982;2:479S–87S. https://doi.org/10.1002/hep.1840020415.

    Article  Google Scholar 

  13. Sharma S, Ahuja V. Liver abscess: complications and treatment. Clin Liver Dis (Hoboken). 2021;18:122–6. https://doi.org/10.1002/cld.1128.

    Article  PubMed  Google Scholar 

  14. Hassani KIM, Ousadden A, Ankouz A, Mazaz K, Taleb KA. Isolated liver tuberculosis abscess in a patient without immunodeficiency: a case report. World J Hepatol. 2010;2:354–7. https://doi.org/10.4254/wjh.v2.i9.354.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Nadasy KA, Domiati-Saad R, Tribble MA. Invasive Klebsiella pneumoniae syndrome in North America. Clin Infect Dis. 2007;45:e25–8. https://doi.org/10.1086/519424.

    Article  CAS  PubMed  Google Scholar 

  16. Siu LK, Yeh K-M, Lin J-C, Fung C-P, Chang F-Y. Klebsiella pneumoniae liver abscess: a new invasive syndrome. Lancet Infect Dis. 2012;12:881–7. https://doi.org/10.1016/S1473-3099(12)70205-0.

    Article  PubMed  Google Scholar 

  17. Zhang Y, Zhao C, Wang Q, Wang X, Chen H, Li H, Zhang F, Li S, Wang R, Wang H. High prevalence of Hypervirulent Klebsiella pneumoniae infection in China: geographic distribution, clinical characteristics, and antimicrobial resistance. Antimicrob Agents Chemother. 2016;60:6115–20. https://doi.org/10.1128/AAC.01127-16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wang JH, Liu YC, Lee SS, Yen MY, Chen YS, Wang JH, Wann SR, Lin HH. Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis. 1998;26:1434–8. https://doi.org/10.1086/516369.

    Article  CAS  PubMed  Google Scholar 

  19. Tu Y-C, Lu M-C, Chiang M-K, Huang S-P, Peng H-L, Chang H-Y, Jan M-S, Lai Y-C. Genetic requirements for Klebsiella pneumoniae-induced liver abscess in an oral infection model. Infect Immun. 2009;77:2657–71. https://doi.org/10.1128/IAI.01523-08.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chang Z, Zheng J, Ma Y, Liu Z. Analysis of clinical and CT characteristics of patients with Klebsiella pneumoniae liver abscesses: an insight into risk factors of metastatic infection. Int J Infect Dis. 2015;33:50–4. https://doi.org/10.1016/j.ijid.2014.12.041.

    Article  PubMed  Google Scholar 

  21. Molton JS, Chan M, Kalimuddin S, Oon J, Young BE, Low JG, Salada BMA, Lee TH, Wijaya L, Fisher DA, Izharuddin E, Koh TH, Teo JWP, Krishnan PU, Tan BP, Woon WWL, Ding Y, Wei Y, Phillips R, Moorakonda R, Yuen KH, Cher BP, Yoong J, Lye DC, Archuleta S. Oral vs intravenous antibiotics for patients with Klebsiella pneumoniae liver abscess: a randomized, controlled noninferiority study. Clin Infect Dis. 2020;71:952–9. https://doi.org/10.1093/cid/ciz881.

    Article  CAS  PubMed  Google Scholar 

  22. Luu S, Spelman D, Woolley IJ. Post-splenectomy sepsis: preventative strategies, challenges, and solutions. Infect Drug Resist. 2019;12:2839–51. https://doi.org/10.2147/IDR.S179902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet. 2011;378:86–97. https://doi.org/10.1016/S0140-6736(10)61493-6.

    Article  PubMed  Google Scholar 

  24. Rubin LG, Schaffner W. Clinical practice. Care of the asplenic patient. N Engl J Med. 2014;371:349–56. https://doi.org/10.1056/NEJMcp1314291.

    Article  CAS  PubMed  Google Scholar 

  25. Casciani F, Trudeau MT, Vollmer CM. Perioperative immunization for splenectomy and the surgeon’s responsibility: a review. JAMA Surg. 2020;155:1068–77. https://doi.org/10.1001/jamasurg.2020.1463.

    Article  PubMed  Google Scholar 

  26. Lenti MV, Corazza GR, Di Sabatino A. COVID-19 and asplenia: a Janus-faced issue. Intern Emerg Med. 2021;16:2341–2. https://doi.org/10.1007/s11739-021-02761-5.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Boam T, Sellars P, Isherwood J, Hollobone C, Pollard C, Lloyd DM, Dennison AR, Garcea G. Adherence to vaccination guidelines post splenectomy: a five year follow up study. J Infect Public Health. 2017;10:803–8. https://doi.org/10.1016/j.jiph.2017.01.006.

    Article  PubMed  Google Scholar 

  28. Davies JM, Lewis MPN, Wimperis J, Rafi I, Ladhani S, Bolton-Maggs PHB, British Committee for Standards in Haematology. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-oncology task force. Br J Haematol. 2011;155:308–17. https://doi.org/10.1111/j.1365-2141.2011.08843.x.

    Article  CAS  PubMed  Google Scholar 

  29. Jones AD, Khan M, Cheshire J, Bowley D. Postsplenectomy prophylaxis: a persistent failure to meet standard? Open Forum Infect Dis. 2016;3:ofw197. https://doi.org/10.1093/ofid/ofw197.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Parker CJ, Kar S, Kirkpatrick P. Eculizumab. Nat Rev Drug Discov. 2007;6:515–6. https://doi.org/10.1038/nrd2369.

    Article  CAS  PubMed  Google Scholar 

  31. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81. https://doi.org/10.1056/NEJMoa1208981.

    Article  CAS  PubMed  Google Scholar 

  32. Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016;29:319–29. https://doi.org/10.1097/QCO.0000000000000279.

    Article  CAS  PubMed  Google Scholar 

  33. Gleesing J, Chiwane S, Rongkavilit C. Gonococcal septic shock associated with eculizumab treatment. Pediatr Infect Dis J. 2012;31:543. https://doi.org/10.1097/INF.0b013e3182503849.

    Article  PubMed  Google Scholar 

  34. Crew PE, McNamara L, Waldron PE, McCulley L, Jones SC, Bersoff-Matcha SJ. Unusual Neisseria species as a cause of infection in patients taking eculizumab. J Infect. 2019;78:113–8. https://doi.org/10.1016/j.jinf.2018.10.015.

    Article  PubMed  Google Scholar 

  35. Borhan WM, Dababo MA, Thompson LDR, Saleem M, Pashley N. Acute necrotizing herpetic tonsillitis: a report of two cases. Head Neck Pathol. 2013;9:119–22. https://doi.org/10.1007/s12105-013-0516-2.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Gómez-Cibeira E, Ivanovic-Barbeito Y, Gutiérrez-Martínez E, Morales E, Abradelo M, Hilario A, Ramos A, Ruiz-Morales J, Villarejo-Galende A. Eculizumab-related progressive multifocal leukoencephalopathy. Neurology. 2016;86:399–400. https://doi.org/10.1212/WNL.0000000000002312.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Han H, Alagusundaramoorthy S, Swanson K, Gardezi AI, Chan MR. Acute Candida albicans peritonitis in a patient with atypical hemolytic uremic syndrome treated with eculizumab. Perit Dial Int. 2019;39:575–6. https://doi.org/10.3747/pdi.2019.00094.

    Article  CAS  PubMed  Google Scholar 

  38. Clancy M, McGhan R, Gitomer J, Inocencio AM, Aldrich C, Iaderosa R, Stevens R. Disseminated cryptococcosis associated with administration of eculizumab. Am J Health Syst Pharm. 2018;75:1018–22. https://doi.org/10.2146/ajhp170708.

    Article  PubMed  Google Scholar 

  39. Czepiel J, Dróżdż M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A, Goldman S, Wultańska D, Garlicki A, Biesiada G. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38:1211–21. https://doi.org/10.1007/s10096-019-03539-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Hung Y-P, Lee J-C, Lin H-J, Liu H-C, Wu Y-H, Tsai P-J, Ko W-C. Clinical impact of Clostridium difficile colonization. J Microbiol Immunol Infect. 2015;48:241–8. https://doi.org/10.1016/j.jmii.2014.04.011.

    Article  CAS  PubMed  Google Scholar 

  41. Solomon DA, Milner DA. ID learning unit: understanding and interpreting testing for Clostridium difficile. Open Forum Infect Dis. 2014;1:ofu007. https://doi.org/10.1093/ofid/ofu007.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Nissle K, Kopf D, Rösler A. Asymptomatic and yet C. difficile-toxin positive? Prevalence and risk factors of carriers of toxigenic Clostridium difficile among geriatric in-patients. BMC Geriatr. 2016;16:185. https://doi.org/10.1186/s12877-016-0358-3.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Gateau C, Couturier J, Coia J, Barbut F. How to: diagnose infection caused by Clostridium difficile. Clin Microbiol Infect. 2018;24:463–8. https://doi.org/10.1016/j.cmi.2017.12.005.

    Article  CAS  PubMed  Google Scholar 

  44. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66:e1–e48. https://doi.org/10.1093/cid/cix1085.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, Wilcox MH. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis. 2021;73:e1029–44. https://doi.org/10.1093/cid/ciab549.

    Article  CAS  PubMed  Google Scholar 

  46. Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, Alam HB, DeMoya MA, Velmahos GC. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg. 2009;144:433–9; discussion 439–440. https://doi.org/10.1001/archsurg.2009.51.

    Article  PubMed  Google Scholar 

  47. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue Y-K, OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422–31. https://doi.org/10.1056/NEJMoa0910812.

    Article  CAS  PubMed  Google Scholar 

  48. Patel D, Senecal J, Spellberg B, Morris AM, Saxinger L, Footer BW, McDonald EG, Lee TC. Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada? JAC Antimicrob Resist. 2023;5:dlac138. https://doi.org/10.1093/jacamr/dlac138.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Lee HS, Plechot K, Gohil S, Le J. Clostridium difficile: diagnosis and the consequence of over diagnosis. Infect Dis Ther. 2021;10:687–97. https://doi.org/10.1007/s40121-021-00417-7.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Wang Y, Schluger A, Li J, Gomez-Simmonds A, Salmasian H, Freedberg DE. Does addition of intravenous metronidazole to Oral vancomycin improve outcomes in Clostridioides difficile infection? Clin Infect Dis. 2020;71:2414–20. https://doi.org/10.1093/cid/ciz1115.

    Article  CAS  PubMed  Google Scholar 

  51. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70:298–304. https://doi.org/10.1016/j.jhin.2008.08.012.

    Article  CAS  PubMed  Google Scholar 

  52. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD, Leney M, Sloan S, Hay CA, Ambrosino DM. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362:197–205. https://doi.org/10.1056/NEJMoa0907635.

    Article  CAS  PubMed  Google Scholar 

  53. Tariq R, Pardi DS, Bartlett MG, Khanna S. Low cure rates in controlled trials of fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Clin Infect Dis. 2019;68:1351–8. https://doi.org/10.1093/cid/ciy721.

    Article  CAS  PubMed  Google Scholar 

  54. Tixier EN, Verheyen E, Luo Y, Grinspan LT, Du CH, Ungaro RC, Walsh S, Grinspan AM. Systematic review with meta-analysis: fecal microbiota transplantation for severe or fulminant Clostridioides difficile. Dig Dis Sci. 2022;67:978–88. https://doi.org/10.1007/s10620-021-06908-4.

    Article  PubMed  Google Scholar 

  55. DeFilipp Z, Bloom PP, Torres Soto M, Mansour MK, Sater MRA, Huntley MH, Turbett S, Chung RT, Chen Y-B, Hohmann EL. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med. 2019;381:2043–50. https://doi.org/10.1056/NEJMoa1910437.

    Article  PubMed  Google Scholar 

  56. Johnson SW, Brown SV, Priest DH. Effectiveness of oral vancomycin for prevention of healthcare facility-onset Clostridioides difficile infection in targeted patients during systemic antibiotic exposure. Clin Infect Dis. 2020;71:1133–9. https://doi.org/10.1093/cid/ciz966.

    Article  CAS  PubMed  Google Scholar 

  57. Garey KW. Perils, pitfalls, and promise of primary prophylaxis for Clostridioides difficile infection. Clin Infect Dis. 2020;71:1140–1. https://doi.org/10.1093/cid/ciz970.

    Article  PubMed  Google Scholar 

  58. McCreery R, Cawcutt K, Cortes-Penfield N, Van Schooneveld T. Oral vancomycin prophylaxis for Clostridioides difficile in high-risk patients receiving systemic antibiotics: what exactly are we preventing? Clin Infect Dis. 2020;71:1798. https://doi.org/10.1093/cid/ciz1216.

    Article  CAS  PubMed  Google Scholar 

  59. Khanna S. My treatment approach to Clostridioides difficile infection. Mayo Clin Proc. 2021;96:2192–204. https://doi.org/10.1016/j.mayocp.2021.03.033.

    Article  CAS  PubMed  Google Scholar 

  60. Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJC, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Yu V, Rihs J, Gorbach SL. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother. 2007;51:1649–55. https://doi.org/10.1128/AAC.01435-06.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Yim J, Lee Y, Kim M, Seo YH, Kim WH, Yong D, Jeong SH, Lee K, Chong Y. Antimicrobial susceptibility of clinical isolates of Bacteroides fragilis group organisms recovered from 2009 to 2012 in a Korean hospital. Ann Lab Med. 2015;35:94–8. https://doi.org/10.3343/alm.2015.35.1.94.

    Article  CAS  PubMed  Google Scholar 

  62. Hansen KCM, Schwensen SAF, Henriksen DP, Justesen US, Sydenham TV. Antimicrobial resistance in the Bacteroides fragilis group in faecal samples from patients receiving broad-spectrum antibiotics. Anaerobe. 2017;47:79–85. https://doi.org/10.1016/j.anaerobe.2017.04.013.

    Article  CAS  PubMed  Google Scholar 

  63. Wang AY, Yu AW, Li PK, Lam PK, Leung CB, Lai KN, Lui SF. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center. Am J Kidney Dis. 2000;36:1183–92. https://doi.org/10.1053/ajkd.2000.19833.

    Article  CAS  PubMed  Google Scholar 

  64. Miles R, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, Bannister KM, Johnson DW. Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney Int. 2009;76:622–8. https://doi.org/10.1038/ki.2009.202.

    Article  PubMed  Google Scholar 

  65. Akoh JA. Peritoneal dialysis associated infections: an update on diagnosis and management. World J Nephrol. 2012;1:106–22. https://doi.org/10.5527/wjn.v1.i4.106.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Li PK-T, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, Johnson DW, Kuijper EJ, Lye W-C, Salzer W, Schaefer F, Struijk DG, International Society for Peritoneal Dialysis. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int. 2010;30:393–423. https://doi.org/10.3747/pdi.2010.00049.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA

    Alexander M. Tatara

Authors
  1. Alexander M. Tatara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander M. Tatara .

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Tatara, A.M. (2023). Abdominal Infection. In: The Infectious Diseases Consult Handbook. Springer, Cham. https://doi.org/10.1007/978-3-031-39474-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-39474-4_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-39473-7

  • Online ISBN: 978-3-031-39474-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation